Axsome Therapeutics AXSM Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's free cash flow margin?
- Axsome Therapeutics (AXSM) reported free cash flow margin of -10.2% in Q1 2026.
- How has Axsome Therapeutics's free cash flow margin changed year-over-year?
- Axsome Therapeutics's free cash flow margin increased by 63.0% year-over-year, from -27.5% to -10.2%.
- What is the long-term trend for Axsome Therapeutics's free cash flow margin?
- Over 3 years (2022 to 2025), Axsome Therapeutics's free cash flow margin has grown at a -60.1% compound annual growth rate (CAGR), from -234.3% to -14.9%.
- What does free cash flow margin mean?
- How much real, spendable cash each sales dollar generates after reinvestment.
- How do you interpret free cash flow margin?
- A high and rising FCF margin is the hallmark of a cash-generative business. Persistent gaps between net margin and FCF margin warrant a look at working capital or capital intensity.
- How does free cash flow margin compare across companies?
- Strong cross-company quality signal; capital-light compounders post structurally higher FCF margins than asset-heavy peers.